oligodendroglioma/glutathione

Lyen an sove nan clipboard la

AtikEsè klinikPatant

Chwazi kalite sòt

13 rezilta yo

Glutathione S-transferase polymorphisms and survival in primary malignant glioma.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

OBJECTIVE The purpose of this research was to investigate the relationship between glutathione S-transferase (GST) polymorphisms and survival, and chemotherapy-related toxicity in 278 glioma patients. METHODS We determined genetic variants for GSTM1, GSTT1, and GSTP1 enzymes by PCR and restriction

Glutathione S-transferase polymorphisms are associated with survival in anaplastic glioma patients.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

BACKGROUND Glutathione S-transferases (GSTs) are polymorphic enzymes that are responsible for glutathione conjugation of alkylators and scavenging of free radicals created by radiation. GST polymorphisms may result in altered or absent enzyme activity and have been associated with survival in

Glutathione-S-transferase variants and adult glioma.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

BACKGROUND Conflicting findings have been reported for associations of primary brain tumors and constitutive polymorphisms in glutathione-S-transferases (GSTs). METHODS We genotyped population-based cases ascertained through rapid case ascertainment and controls identified through random-digit

Concurrent hypermethylation of multiple genes is associated with grade of oligodendroglial tumors.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Current evidence suggests that epigenetic changes play an important role in the evolution of human cancers. In this study, we evaluated whether hypermethylation of CpG islands at the gene promotor regions of several tumor-related genes is involved in the carcinogenesis of oligodendroglial tumors. We

Clinical, histological, and immunohistochemical features predicting 1p/19q loss of heterozygosity in oligodendroglial tumors.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

To identify a better diagnostic criteria for oligodendroglial tumors, we investigated the clinical, histological, and immunohistochemical features that would be able to predict a 1p/19q loss of heterozygosity (LOH) in these tumors. We performed a PCR-based LOH test with the 1p and 19q microsatellite

Expression of glutathione S-transferase T1 (GSTT1) in human brain tumours.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Glutathione S-transferases (GSTs) play a central role in a number of metabolic processes. Glutathione S-transferase T1 (GSTT1) is a polymorphic cytosolic enzyme and a member of the theta class of GSTs. Typical substrates for GSTT1 are industrial compounds, such as dichloromethane and ethylene oxide.

Differential expression of drug resistance genes and chemosensitivity in glial cell lineages correlate with differential response of oligodendrogliomas and astrocytomas to chemotherapy.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

The two principal subtypes of glial neoplasms, astrocytomas and oligodendrogliomas, exhibit striking differences in response to chemotherapy. This differential chemosensitivity might be explained by the specific genetic alterations causing gliomas but could also be attributable to specific

Metabolite-cycled density-weighted concentric rings k-space trajectory (DW-CRT) enables high-resolution 1 H magnetic resonance spectroscopic imaging at 3-Tesla.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Magnetic resonance spectroscopic imaging (MRSI) is a promising technique in both experimental and clinical settings. However, to date, MRSI has been hampered by prohibitively long acquisition times and artifacts caused by subject motion and hardware-related frequency drift. In the present study, we

Immunocytochemical mapping of the phosphatase and tensin homolog (PTEN/MMAC1) tumor suppressor protein in human gliomas.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

PTEN/MMAC1 (phosphatase and tensin homolog/mutated in multiple advanced cancers 1) is a tumor suppressor gene, the inactivation of which is an important step in the progression of gliomas to end-stage glioblastoma multiforme. We examined the distribution of PTEN protein in 49 primary human gliomas

In vitro drug response and molecular markers associated with drug resistance in malignant gliomas.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

OBJECTIVE Drug resistance in malignant gliomas contributes to poor clinical outcomes. We determined the in vitro drug response profiles for 478 biopsy specimens from patients with the following malignant glial histologies: astrocytoma (n = 71), anaplastic astrocytoma (n = 39), glioblastoma

Evaluation of the efficiency of chemotherapy in in vivo orthotopic models of human glioma cells with and without 1p19q deletions and in C6 rat orthotopic allografts serving for the evaluation of surgery combined with chemotherapy.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

BACKGROUND Malignant gliomas of the central nervous system remain associated with dismal prognoses because of their diffuse invasion of the brain parenchyma. Very few experimental models that mimic clinical reality are available today to test potentially new therapies. The authors set up

Metabolic Profiling of IDH Mutation and Malignant Progression in Infiltrating Glioma.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Infiltrating low grade gliomas (LGGs) are heterogeneous in their behavior and the strategies used for clinical management are highly variable. A key factor in clinical decision-making is that patients with mutations in the isocitrate dehydrogenase 1 and 2 (IDH1/2) oncogenes are more likely to have a

Profiling the effects of isocitrate dehydrogenase 1 and 2 mutations on the cellular metabolome.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Point mutations of the NADP(+)-dependent isocitrate dehydrogenases 1 and 2 (IDH1 and IDH2) occur early in the pathogenesis of gliomas. When mutated, IDH1 and IDH2 gain the ability to produce the metabolite (R)-2-hydroxyglutarate (2HG), but the downstream effects of mutant IDH1 and IDH2 proteins or

Antre nan paj
facebook nou an

Herbal & Natural Medicine

Baz done ki pi konplè remèd fèy medsin te apiye nan syans

Travay nan 55 lang
Geri èrbal te apiye nan syans
Remèd fèy rekonesans pa imaj
Kat entèaktif GPS - tag zèb sou kote (vini byento)
Li piblikasyon syantifik ki gen rapò ak rechèch ou an
Search remèd fèy medsin pa efè yo
Izeganize enterè ou yo ak rete kanpe fè dat ak rechèch la nouvèl, esè klinik ak rive

Tape yon sentòm oswa yon maladi epi li sou remèd fèy ki ta ka ede, tape yon zèb ak wè maladi ak sentòm li itilize kont.
* Tout enfòmasyon baze sou rechèch syantifik pibliye